Skip to main content
TipRanks
Go Ultimate75% OFF

Compare AFT Pharmaceuticals Ltd. (AFP) vs. Competitors

6 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
AU:AFPAFT Pharmaceuticals Ltd.AUD 3.60AUD 384.75M31.9732.84%Moderate BuyUnlock the AU:AFP analyst price target with TipRanks PremiumAU:AFPUnlock the AU:AFP top-analyst price target with TipRanks Premium
NZ:EBOEBOS Group LimitedNZD 21.40NZD 4.47B16.30-25.25%Strong BuyUnlock the NZ:EBO analyst price target with TipRanks PremiumAU:AFP vs NZ:EBOUnlock the NZ:EBO top-analyst price target with TipRanks Premium
NZ:FPHFisher & Paykel Healthcare Corporation LimitedNZD 48.48NZD 28.52B60.6027.31%Strong BuyUnlock the NZ:FPH analyst price target with TipRanks PremiumAU:AFP vs NZ:FPHUnlock the NZ:FPH top-analyst price target with TipRanks Premium
NZ:PEBPacific Edge LimitedNZD 0.28NZD 341.52M-7.1857.14%HoldUnlock the NZ:PEB analyst price target with TipRanks PremiumAU:AFP vs NZ:PEBUnlock the NZ:PEB top-analyst price target with TipRanks Premium
NZ:TRUTruScreen Group Ltd.NZD 0.01NZD 8.38M-2.58-47.37%―Unlock the NZ:TRU analyst price target with TipRanks PremiumAU:AFP vs NZ:TRUUnlock the NZ:TRU top-analyst price target with TipRanks Premium
NZ:RUARua Bioscience Ltd.NZD 0.03NZD 11.77M-2.60-7.14%―Unlock the NZ:RUA analyst price target with TipRanks PremiumAU:AFP vs NZ:RUAUnlock the NZ:RUA top-analyst price target with TipRanks Premium

Performance Comparison

-50%-25%0%25%50%75%100%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
AU:AFPAFT Pharmaceuticals Ltd.3.600.8932.84%
NZ:EBOEBOS Group Limited21.40-6.48-23.24%
NZ:FPHFisher & Paykel Healthcare Corporation Limited48.4812.0933.22%
NZ:PEBPacific Edge Limited0.280.1162.72%
NZ:TRUTruScreen Group Ltd.0.01-0.01-44.44%
NZ:RUARua Bioscience Ltd.0.03-0.00-7.14%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts